- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
GSK Announces Nominations Committee Board Changes
Glaxo SmithKline (GSK) has announced that Sir Philip Hampton has been appointed Chairman of the Nominations Committee, effective today (January 27).
Glaxo SmithKline (GSK) has announced that Sir Philip Hampton has been appointed Chairman of the Nominations Committee, with effect from today (January 27). He replaces Sir Christopher Gent, who will continue to serve as a member of the Committee for the remainder of his tenure on the Board.
In addition, Ms Lynn Elsenhans has also been appointed a member of the Committee.
The membership of the Nominations Committee is now:
Sir Philip Hampton - CommitteeChairman Designate
Sir Christopher Gent - Chairman
Professor Sir Roy Anderson - Scientific & Medical Expert
Lynn Elsenhans - Non Executive Director
Judy Lewent - Audit & Risk Committee Chairman
Sir Deryck Maughan - Senior Independent Director
Tom de Swaan - Remuneration Committee Chairman
